Dupilumab shows longterm safety and efficacy in patients
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Mette Deleuran, MD, DMSc, Diamant Thaçi, MD, Lisa A. Beck, MD, Marjolein de Bruin-Weller, MD, Ph. D, Andrew Blauvelt, MD, MBA, Seth Forman, MD, Robert Bissonnette, MD, Kristian Reich, MD, Weily Soong, MD, Iftikhar Hussain, MD, Peter Foley, MD, Michihiro Hide, MD, Ph. D, Jean-David Bouaziz, MD, Ph. D, Joel M. Gelfand, MD, MSCE, Lawrence Sher, MD, Marie L. A. Schuttelaar, MD, Ph. D, Chen Wang, Ph. D, Zhen Chen, Ph. D, MS, MA, Bolanle Akinlade, MD, Abhijit Gadkari, Ph. D, Laurent Eckert, Ph. D, John D. Davis, Ph. D, Manoj Rajadhyaksha, Ph. D, Heribert Staudinger, MD, Ph. D, Neil M. H. Graham, MD, Gianluca Pirozzi, MD, Ph. D, Marius Ardeleanu, MD Journal of the American Academy of Dermatology Volume 82 Issue 2 Pages 377 -388 (February 2020) DOI: 10. 1016/j. jaad. 2019. 074 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Journal of the American Academy of Dermatology 2020 82377 -388 DOI: (10. 1016/j. jaad. 2019. 074) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Journal of the American Academy of Dermatology 2020 82377 -388 DOI: (10. 1016/j. jaad. 2019. 074) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Journal of the American Academy of Dermatology 2020 82377 -388 DOI: (10. 1016/j. jaad. 2019. 074) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
- Slides: 4